干细胞治疗儿童心力衰竭的综述
本综述聚焦儿童先天性心脏病术后晚期心力衰竭的治疗难题,指出心脏移植受限于器官短缺,而基于成人证据的细胞治疗在儿童中具有更高再生潜力的前景。文章评估了从骨髓单个核细胞到心肌球来源干细胞等多种干细胞类型的潜在应用,并讨论了当前挑战与未来策略。
要点
- 儿童先心病术后晚期心衰仍是严重临床问题,心脏移植受限于供体短缺。
- 成人细胞治疗证据提示安全有效,儿童再生能力更高,干细胞治疗前景可期。
- 综述涵盖骨髓单个核细胞至心肌球来源干细胞等多种细胞类型。
核心结论
- 干细胞治疗可能成为儿童心力衰竭的有前景治疗选择,但需解决当前挑战并发展新策略。
研究设计与样本
- 综述类文章,基于既往试验和研究发现,评估多种干细胞类型用于儿童细胞治疗。
主要发现
- 儿童心脏病学、外科和重症监护的进步显著改变了先心病患儿结局,但分期术后晚期心衰仍受关注。
- 成人细胞治疗证据积累提示其治疗心力衰竭的安全性和有效性。
- 儿童再生能力似乎高于成人,支持干细胞治疗在儿童心衰中的探索。
临床怎么用
- 临床可关注干细胞治疗作为儿童心衰的潜在选项,尤其心脏移植供体受限时。
局限性
- 综述基于既往试验和研究成果,未报告具体样本量、阈值或疗效数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Significant achievements in paediatric cardiology, surgical treatment and intensive care of congenital heart disease have drastically changed clinical outcomes for paediatric patients. Nevertheless, late-onset heart failure in children after staged surgeries still remains a serious concern in the medical community. Heart transplantation is an option for treatment; however, the shortage of available organs is a persistent problem in many developed countries. In order to resolve these issues, advanced technologies, such as innovative mechanical circulatory support devices and regenerative therapies, are strongly desired. Accumulated evidence regarding cell-based cardiac regenerative therapies has suggested their safety and efficacy in treating adult heart failure. Given that young children seem to have a higher regenerative capacity than adults, stem cell-based therapies appear a promising treatment option for paediatric heart failure as well. Based on the findings from past trials and studies, we present the potential of various different types of stem cells, ranging from bone marrow mononuclear cells to cardiosphere-derived stem cells for use in paediatric cell-based therapies. Here, we assess both the current challenges associated with cell-based therapies and novel strategies that may be implemented in the future to advance stem cell therapy in the paediatric population.
引用
- Ishigami S, Sano T, Krishnapura S, et al. An overview of stem cell therapy for paediatric heart failure. Eur J Cardiothorac Surg. 2020. PMID: 32588055. doi:10.1093/ejcts/ezaa155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。